IP6 Analogue PEG Solubility for C. difficile Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Clostridium difficile infection (CDI) are inadequate due to the inability of myo-inositol hexakisphosphate (IP6) to remain active in the colon lumen, where high calcium concentrations precipitate it, preventing effective cleavage of toxins TcdA and TcdB.
Innovation Solution
Development of small-molecule analogues of IP6 with improved solubility, such as myo-inositol-pentakisphosphate-2-PEG(400), which includes a polyethylene glycol chain to maintain solubility in the presence of calcium, facilitating the cleavage of TcdB cysteine protease domain in the colon lumen.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If myo-inositol hexakisphosphate (IP6) is used to trigger toxin cleavage, then the therapeutic effect is achieved, but the high calcium concentrations in the colon precipitate IP6 and prevent it from being active
Solution Approach 1:
The patent combines IP6 with polymeric binders (such as polyethylene glycol, carboxymethylcellulose, or dextran) to create composite structures. These polymeric carriers protect IP6 from calcium precipitation while maintaining its ability to trigger toxin cleavage, thereby resolving the contradiction between therapeutic activity and solubility stability in the high-calcium colon environment.
Solution Approach 2:
The polymeric binder acts as an intermediary between IP6 and the calcium-rich colon lumen. The polymer shield prevents direct interaction between IP6 and calcium ions that would cause precipitation, while still allowing IP6 to perform its function of triggering toxin autoprocessing when it reaches the target site.
2Stability of the object's composition
If polymeric binders are used to protect IP6 from precipitation, then solubility is improved, but the compounds failed in clinical trials
Solution Approach 1:
The patent modifies the molecular structure of IP6 by changing parameters such as the degree of phosphorylation (creating IP5, IP4 derivatives) or the specific polymeric binder used. These parameter changes optimize both the solubility protection and the biological activity, addressing the failures of previous formulations that did not achieve the right balance between stability and efficacy.
Solution Approach 2:
The invention applies different functional properties to different parts of the compound system. The polymeric binder provides solubility and stability in the calcium-rich environment, while the IP6 core maintains its toxin-triggering activity. This local differentiation of functions allows the compound to overcome the limitations of previous approaches.
3Stability of the object's composition
If small-molecule analogues with polyethylene glycol chains are used, then solubility in the presence of calcium is maintained, but the molecular complexity increases
Solution Approach 1:
The patent systematically varies parameters of the small-molecule analogues, such as the length of the polyethylene glycol chain or the position of phosphate groups, to achieve optimal solubility and activity. This structured approach to parameter optimization allows for improved performance while maintaining reasonable molecular complexity compared to large polymeric formulations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These analogues effectively cleave TcdB in the presence of calcium, offering a more stable and active therapeutic option for CDI treatment by remaining soluble and active in the colon lumen, thereby rendering the toxins harmless.
Implementation Method 1
small-molecule analogues of IP6 that are provided as an oral therapy to trigger the cleavage of the toxin in the colon lumen... the present invention provides new analogues of IP6 with improved solubility... a polyethylene glycol (PEG) chain shown here as a non-limiting example, is attached to the molecule to render it soluble in the colon lumen, at the concentrations of calcium present therein
Implementation Method 2
C. difficile enterotoxin (toxin A, TcdA) and cytotoxin (toxin B, TcdB) are the main contributors to the symptoms of disease... a third domain causing the cleavage of the toxic domain by autoproteolysis... Reineke et al. (Nature 2007, 446, 415) identified myo-inositol hexakisphosphate (IP6) as the natural trigger of TcdA/TcdB autoprocessing in the cell cytosol
Data Source
Figure 1A~1B
Figure 2
Figure 3
AI summary
The invention relates to a compound described by a general formula (1), wherein each X independently can be OPO3 2-, OPSO2 2- or OSO3 - ; R1 comprises a solubility function such as a polyethylene glycol moiety and each X independently can be OPO3 2-, OPSO2 2-, - or OSO3 -; and Z is an alkyl chain comprising 1 to 3 carbon and/or hetero atoms. The invention further relates to polysulfate derivatives or mixed polyphosphate/sulphate derivatives of six-membered cyclic polyols for use in the therapy of infection by Clostridium difficile.